Drug Trial Radar · NCT06304740
Safety and Pharmacokinetics of Subcutaneous Dose of IMG-007 in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Dec 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
16
Actual
Start
Mar 6, 2024
Primary completion
Aug 28, 2024
Study completion Aug 28, 2024
Sponsor
- Lead sponsor
- Inmagene LLCIndustry
- Sponsor type
- Industry
- First posted
- Mar 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a double-blind, randomized, placebo-controlled study to assess the safety and PK profile of a single subcutaneous dose of IMG-007 in healthy participants. The study will comprise of a 5-week screening period, a 3-day In-patient Period in a clinical research unit (CRU) and an Out-patient Follow-up Period up to 127 days. The study will include 3 dose cohorts which will be enrolled sequentially. Participants will receive a single subcutaneous dose of IMG-007 or placebo at Baseline according to their assigned dose.
Conditions
- Healthy Volunteers
Interventions
IMG-007Drug
Subcutaneous injection of IMG-007
PlaceboDrug
Subcutaneous Injection of Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse Event EvaluationTime frame: Up to 18 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Linear Clinical Research
Perth, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.